Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial.

ABSTRACT:

Importance

Peritoneal metastasis in patients with locally advanced colon cancer (T4 stage) is estimated to recur at a rate of approximately 25% at 3 years from surgical resection and is associated with poor prognosis. There is controversy regarding the clinical benefit of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) in these patients.

Objective

To assess the efficacy and safety of intraoperative HIPEC in patients with locally advanced colon cancer.

Design, setting, and participants

This open-label, phase 3 randomized clinical trial was conducted in 17 Spanish centers from November 15, 2015, to March 9, 2021. Enrolled patients were aged 18 to 75 years with locally advanced primary colon cancer diagnosed preoperatively (cT4N02M0).

Interventions

SUBMITTER: Arjona-Sanchez A 

PROVIDER: S-EPMC10134040 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature